AHA comments on the Health Resources and Services Administration’s (HRSA) information collection request (ICR) regarding the expected costs of its 340B Rebate Model Pilot Program.

The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s estimates, and HRSA should delay the program’s ...

Several recent policy proposals are placing new pressures on the 340B drug pricing program, a decades-old federal initiative many hospitals and health systems depend on to offset the costs of care for ...

The 340B program, enacted by Congress in 1992, requires pharmaceutical companies to sell medications to rural hospitals at ...

The 340B drug discount program incentivizes hospitals to purchase outpatient clinics and prescribe more and higher-cost drugs — behaviors that tend to increase costs for the federal government and ...

An obscure, supposedly free federal program is blowing a hole in state budgets – by depriving state governments of billions in corporate tax revenue and inflating costs for their public employee ...

The American Hospital Association wants the Health Resources and Services Administration to levy monetary penalties against Johnson & Johnson if the drug company continues with its plan to give 340B ...

The Health Resources and Services Administration has sent a letter to Johnson & Johnson warning the company of the consequences if it proceeds with its planned 340B rebate proposal. In a Sept. 17 ...

The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...

Following Eli Lilly and Johnson & Johnson, Sanofi is aiming to change how it participates in the 340B program, a federal drug pricing program created in 1992, The Wall Street Journal reported Nov. 22.